Recombinant DNA (rDNA) technology is a novel technique that has led to advances in a number of different fields such as drug development, agriculture, and research. Recombinant DNA technology has introduced new classes of organisms namely genetically modified organism (GMO) or living modified organism (LMO). It can develop genetically modified crops (BT cotton), cloned animals, bio pesticides, biofuel, and gene therapy successfully. rDNA technology has triggered the biopharmaceutical industries towards the development of various rDNA products such as CAR-T cell therapy and bispecific and monoclonal antibodies, in turn, favoring the growth of the recombinant DNA technology market. Moreover, the gene-editing system –Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) – holds great potential for the development of vaccines and drugs, as it plays a major role in the stability and enhancement of immunity.
Market Dynamics
The increasing adoption of inorganic strategies such as partnership is expected to drive the market growth over the forecast period. For instance, in September 2020, according to the data published by the National Center for Biotechnology Information, Serum Institute of India Pvt., Ltd. (SII), a biotechnology and Biopharmaceutical Company based in India, and the Indian Council of Medical Research (ICMR), an autonomous organization under the Department of Health Research, partnered for the clinical development of two global vaccine candidates. The first one is ChAdOx1-S, which is a non-replicating viral vector vaccine developed by the University of Oxford/AstraZeneca. This vaccine is undergoing phase III clinical trials in Brazil. Phase II/III bridging studies have been initiated by ICMR at 14 clinical trial sites. ICMR-National Institute for Research in Tuberculosis (NIRT), Chennai is the lead institution.
Moreover, in September 2020, ICMR and Serum Institute of India Pvt., Ltd. (SII) have also partnered for the clinical development of a glycoprotein subunit nanoparticle adjuvanted vaccine, developed by Novavax, Inc., biotechnology company that develops vaccines to counter serious infectious diseases from the U.S. The trial will be initiated in the second half of October 2020 after the vaccine is manufactured by SII. The trial is led by ICMR-National AIDS Research Institute (NARI), Pune, India.
Key features of the study:
Detailed Segmentation:
“*” marked represents similar segmentation in other categories in the respective section.
Table of Contents
*Browse 38 market data tables and 26 figures on "Global Recombinant DNA Technology Market” - forecast to 2030
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients